MedPath

Tocopherol

Generic Name
Tocopherol
Drug Type
Small Molecule
CAS Number
1406-66-2
Unique Ingredient Identifier
R0ZB2556P8
Background

Tocopherol exists in four different forms designated as α, β, δ, and γ. They present strong antioxidant activities, and it is determined as the major form of vitamin E. Tocopherol, as a group, is composed of soluble phenolic compounds that consist of a chromanol ring and a 16-carbon phytyl chain. The classification of the tocopherol molecules is designated depending on the number and position of the methyl substituent in the chromanol ring. The different types of tocopherol can be presented trimethylated, dimethylated or methylated in the positions 5-, 7- and 8-. When the carbons at position 5- and 7- are not methylated, they can function as electrophilic centers that can trap reactive oxygen and nitrogen species. Tocopherols can be found in the diet as part of vegetable oil such as corn, soybean, sesame, and cottonseed. It is currently under the list of substances generally recognized as safe (GRAS) in the FDA for the use of human consumption.

Indication

Tocopherol can be used as a dietary supplement for patients with a deficit of vitamin E; this is mainly prescribed in the alpha form. Vitamin E deficiency is rare, and it is primarily found in premature babies of very low birth weight, patients with fat malabsorption or patients with abetalipoproteinemia.

Tocopherol, due to its antioxidant properties, is studied for its use in prevention or treatment in different complex diseases such as cancer, atherosclerosis, cardiovascular diseases, and age-related macular degeneration.

Associated Conditions
Vitamin E Deficiency
Associated Therapies
Skin Care

Simon Two-Stage Design Shows Promise for Streamlining Parkinson's Disease Trials

• Analysis of two clinical trials suggests the Simon 2-Stage futility design is feasible for evaluating treatments in early Parkinson's disease, potentially accelerating drug discovery. • The Simon 2-Stage design allows for earlier stopping points based on interim analysis, saving time and resources in identifying effective therapies. • Researchers propose using a five-point worsening on the UPDRS motor score as the primary outcome measure with a 12-month follow-up period in such trials. • The analysis indicates that smaller clinical trials (fewer than 200 participants) using this methodology are feasible, reducing the need for larger, costly RCTs.
© Copyright 2025. All Rights Reserved by MedPath